A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin (Eluminate-3)
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin (Eluminate-3)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with placebo in adults with Type 2 Diabetes Mellitus (T2DM), treated with a background insulin and other background glucose-lowering medication(s)
Inclusion Criteria:
Exclusion Criteria:
information.center@astrazeneca.com1-877-240-9479
North York, Ontario M6B 3H7, Canada
Liangyugang, 222002, China
Asahikawa-shi, 070-8530, Japan
Kamakura-shi, 247-0056, Japan
Kashiwa-shi, 277-0825, Japan
Jongno-gu, 110-746, South Korea
Muang, 50200, Thailand
Mueang, 20000, Thailand